Mymetics Corporation operates as an international biotechnology company focused on developing vaccines to combat a range of diseases. The company exploits its knowledge and intellectual property related to mucosal immunology and virosomes to develop vaccines. It uses these approaches for a portfolio of five vaccines, of which three are in clinical trials stages. Mymetics Corporation developed its portfolio using a mixture of in-house resources, outsourcing, and collaborations with major pharmaceutical companies. Its vaccine portfolio addresses HIV, RSV, herpes, influenza, and malaria. The company's key technologies, which can be exploited across a range of other vaccines, focus on mucosal immunology and the use of virosomes as a delivery method/adjuvant. Virosome based vaccines benefit from their immunogenicity, safety profile, and stability. Mucosal immunology focuses on inducing antibody production at the body's mucosal surfaces, through which most pathogens enter the body. Mymetics Corporation plans to develop its vaccines up to the conclusion of Phase II trials, by which point partnerships with large pharmaceuticals will be entered into. The company also focuses on applying its virosomal approach and mucosal immunity approach to a range of vaccines through a combination of selective acquisitions, in-house development, partnerships, and out-licensing. It was formerly known as Hippocampe S.A. and changed its name to Mymetics Corporation on July 31, 2001. The company was founded in 1990 and is based in Epalinges, Switzerland.

INCORPORATED: in Delaware in November 1996 as ICHOR Corp. to succeed a Pennsylvania corporation organized on July 20, 1994 as PDG Remediation, Inc., a wholly owned subsidiary of PDG Environmental, Inc. Name changed to Mymetics Corp. in July 2001.

SUBSIDIARIES: